Radiopharmacy is our passion
Bridging preclinical research and clinical development to accelerate the clinical implementation of unique cancer diagnostics and therapeutics for the long term benefit of cancer patients.
About Us
Innovation is our driving force
SCINTOMICS has a constantly developing and evolving portfolio of unique radiopharmaceuticals and paves the way for clinical development for such Theranostic. We are proud of the fact that several radiopharmaceuticals from our portfolio are currently developed in clinical studies or on the way to market approval in the near future. The certainty that these developments will open up new avenues for the diagnosis and therapy of cancer patients is a great motivation for us to continue mission with great commitment and enthusiasm.
Technologies
Radiohybrid Technology
A novel class of Radiopharmaceuticals. Radiohybrids are Radiopharmaceuticals that address all aspects of theranostics: that can be labeld with 18F, 68Ga or other positron-emitting radiometals for PET (Dx) or with therapeutic radionuclides as 177Lu or 225Ac for radioligand therapy (Tx).
Read more
Radiohybrid Technology
On-Cartridge Drying
Isotopic exchange
Metabolic Stabilization
PSMA ITS
sioPSMAs
1 June 2023
U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA® (Flotufolas
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced U.S. Food and Drug Administration (FDA) approval for its optimized, high-affinity radiohybrid (rh) Prostate-Specific Membrane Antigen (PSMA)-targeted PET imaging agent, POSLUMA® (flotufolastat F 18) injection (formerly referred to as 18F-rhPSMA-7.3)
Read more
19 April 2021
Eckert & Ziegler Strahlen- und Medizintechnik AG Acquires Dire
Würzburg (Germany), April 19th, 2021 – Eckert & Ziegler Strahlen- und Medizintechnik AG has acquired several share packages from the founders of PentixaPharm GmbH. Together with another internal share transfer, Eckert & Ziegler AG will directly hold a total of about 83% of the shares in the company as of closing of the transactions.
Read more
5 January 2021
Blue Earth Diagnostics Acquires Exclusive, Worldwide Rights to
Blue Earth Diagnostics has exercised an option to acquire exclusive, worldwide rights to therapeutic applications of novel radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) technology in prostate cancer
Read more